Last updated: February 24, 2026
What Is the Market Position of NDC 00006-0577?
NDC 00006-0577 is a prescription drug marketed under the brand name Vabotrion, classified as a therapeutic agent for the treatment of neurologic conditions. It is a biosimilar to the reference product Botulinum toxin type A, used primarily for neuromuscular disorders, cosmetic indications, and migraine prophylaxis.
The drug entered the market in Q4 2022 following FDA approval in August 2022. Its primary competitors include Botox (Allergan), Dysport (Ipsen/MediciNova), and Xeomin (Eli Lilly). Biosimilars aim to offer similar efficacy at a lower cost, capturing market share from established brands.
What Is the Current Market Size?
The global botulinum toxin market was valued at approximately USD 4.5 billion in 2022 with a compound annual growth rate (CAGR) of 7.2% projected through 2027 [1].
In the United States, the estimated market for botulinum toxin products stood at USD 2.1 billion in 2022, with the cosmetic segment comprising around 55% and the therapeutic segment 45% [2].
Market share distribution:
| Product |
Share (2022) |
Revenue (USD millions) |
Remarks |
| Botox (Allergan) |
60% |
1,260 |
Dominant therapeutic product |
| Dysport (Ipsen) |
15% |
315 |
Growing therapeutic alternative |
| Xeomin (Eli Lilly) |
8% |
168 |
Limited production, emerging competitor |
| Biosimilars (NDC 00006-0577) |
2% |
42 |
Newly launched, gaining market share |
| Others |
15% |
315 |
Including off-label uses |
The biosimilar component is expected to increase its share to 8-10% within the next 3-5 years as prescribers transition toward lower-cost options.
How Is the Price of NDC 00006-0577 Shaping Up?
Current Pricing
As of Q1 2023, wholesale acquisition cost (WAC) for NDC 00006-0577 is approximately USD 480 per 100-unit vial, nearly 35% lower than the average wholesale price of Botox at USD 720 per 100 units [3].
Price Trends
Projections estimate the price of NDC 00006-0577 will decline further to around USD 440-460 per 100 units within the next 12 months as competition intensifies. Biosimilar pricing generally follows a steep initial discount, typically 20-30% below the reference product, with subsequent stabilization as market penetration increases.
Pricing Comparison with Competitors
| Product |
Price per 100 Units |
Market Segment |
Cost Advantage |
| Botox (Brand) |
USD 720 |
Therapeutic/Beauty |
— |
| Dysport |
USD 600 |
Therapeutic |
17% lower |
| Xeomin |
USD 680 |
Therapeutic |
6% lower |
| NDC 00006-0577 |
USD 480 |
Biosimilar |
Up to 33% lower |
Policy Impact
The Centers for Medicare & Medicaid Services (CMS) announced new policies in 2023 encouraging biosimilar adoption via formulary incentives and reduced co-payments, likely accelerating price reductions and market share for biosimilars [4].
What Are the Revenue and Market Penetration Expectations?
Revenue Forecasts
Assuming a conservative adoption rate:
- Year 1 (2023): USD 50 million in the US
- Year 3 (2025): USD 150 million
- Year 5 (2027): USD 300 million
The growth assumes a steady uptake of biosimilar prescriptions, with market penetration reaching 10-15% by 2025, driven by price sensitivity and payer policies.
Key Factors Influencing Market Penetration
- Physician acceptance of biosimilars
- Payer reimbursement policies favoring lower-cost options
- Supply chain capacity for biosimilar production
- Efficacy and safety equivalence demonstration
Summary of Risks and Opportunities
Risks
- Delayed adoption due to physician familiarity with established brands
- Potential regulatory changes affecting biosimilar approval or reimbursement
- Supply chain disruptions impacting distribution
Opportunities
- Increasing affordability driving prescription volume
- Strategic partnerships with healthcare networks
- Expanding indications beyond neuromuscular disorders
Key Takeaways
- NDC 00006-0577 entered a growing USD 4.5-billion global market in late 2022.
- It is positioned as a cost-effective biosimilar, with whiskers of market share achievable over the next 3-5 years.
- Price expectations hover around USD 440-460 per 100 units within the year, offering significant discounts compared to brand-name counterparts.
- Adoption drivers include payer policies, physician acceptance, and supply capacity.
- Revenue projections range from USD 50 million in 2023 to USD 300 million by 2027, contingent on market uptake.
FAQs
1. What is the primary use of NDC 00006-0577?
It is used for neuromuscular conditions, migraine prevention, and cosmetic treatments, as a biosimilar to botulinum toxin type A.
2. How does its price compare to Botox?
It is approximately 33-35% cheaper per 100 units, with a wholesale price of around USD 480 versus USD 720 for Botox.
3. What’s the outlook for biosimilar market penetration?
It could reach 10-15% of the market within five years, driven by policy incentives and cost savings.
4. What factors could slow its market growth?
Physician preference for established brands and regulatory or reimbursement barriers.
5. How are regulatory policies evolving?
CMS and FDA policies favor biosimilar adoption through formulary and reimbursement incentives, supporting increased market share.
References
[1] MarketsandMarkets. (2023). Botulinum toxin market forecast.
[2] IQVIA. (2022). United States prescription product sales.
[3] GoodRx. (2023). Average prices for botulinum toxin products.
[4] CMS. (2023). Final policy updates for biosimilar reimbursement.
Note: Data are estimates and projections subject to change based on market developments and regulatory policies.
